Subhendu K. Boral

88 Ghoshpara Road, Barrackpore
Kolkata, WB 700120, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Clinical evaluation of faricimab in real-world neovascular age-related macular degeneration in India: a multicenter observational study.

Clinical evaluation of faricimab in real-world neovascular age-related macular degeneration in India: a multicenter observational study.

Journal: BMC ophthalmology

Published: December 24, 2025

Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India.

Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India.

Journal: Indian journal of ophthalmology

Published: December 15, 2025

"Micro-Viscous Fluid Control": A Simple Homemade New Tool to Access Subretinal Space in a Controlled Way.

"Micro-Viscous Fluid Control": A Simple Homemade New Tool to Access Subretinal Space in a Controlled Way.

Journal: Retina (Philadelphia, Pa.)

Published: January 21, 2025

CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.

CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: January 03, 2025

"Caution with choroidals" - choose the right one at right time.

"Caution with choroidals" - choose the right one at right time.

Journal: Indian journal of ophthalmology

Published: December 02, 2024

Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study.

Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study.

Journal: BMC ophthalmology

Published: November 20, 2024

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: October 25, 2024

Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study.

Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: October 21, 2024

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study.

Journal: BMC ophthalmology

Published: October 16, 2024

Efficacy and safety of large-scale use of vancomycin injection in infusion bottle during vitreoretinal procedures.

Efficacy and safety of large-scale use of vancomycin injection in infusion bottle during vitreoretinal procedures.

Journal: Oman journal of ophthalmology

Published: February 06, 2024

Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.

Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: January 11, 2024

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.

Journal: American journal of ophthalmology case reports

Published: December 29, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026